The following stories appear in full on today's Vidyya Medical News Service Web site.
AstraZeneca Pharmaceuticals announced this week that it has received approval from the US Food and Drug Administration for 72-hour infusion of Naropin (ropivacaine HCL), a long-acting anesthetic indicated for the production of local or regional anesthesia for surgery, post-operative pain management and for obstetrical procedures. Naropin is the only FDA approved, long-acting anesthetic with a 72-hour infusion indication. Adverse effects have been reported and include: hypotension, nausea, vomiting, bradycardia, fever, paresthesia and back pain.
Vidyya continues to bring you the information you need. Synthroid, the most commonly prescribed medication in the US is indicated as replacement or supplemental therapy in patients of any age or state (including pregnancy) with hypothyroidism. The medication is also indicated as a pituitary TSH suppressant in the treatment or prevention of various types of euthyroid goiters, including thyroid nodules, subacute or chronic lymphocytic thyroiditis Hashimoto’s), multinodular goiter, and in conjunction with surgery and radioactive iodine therapy in the management of thyrotropin-dependent well-differentiated papillary or follicular carcinoma of the thyroid. You can get the full prescribing information for Synthroid, as well as Naropin, in today's issue.
Remembering a memory....A spontaneous reactivation mechanism that makes the brain replay events over and over reinforces the same cellular event that led to the initial formation of a memory. The reinforcement is critical for creating the cell-to-cell connections that constitute long-term memories. Exciting research published in the November 10 issue of Science sheds light on what makes a memory, well... memorable.
The CDC is inviting comments on the "Revised Guidelines for HIV Counseling, Testing, and Referral." Comments must be submitted in writing on or before November 30, 2000 to the Technical Information and Communications Branch, Mailstop E-49, Division of HIV/AIDS Prevention, National Center for HIV, STD, and TB Prevention, Centers for Disease Control and Prevention (CDC), 1600 Clifton Road, N.E., Atlanta, Georgia 30333; Fax: 404-639-2007; E-mail:
email@example.com. Of course, you can read the full document in tody's Vidyya.
Vidyya has been monitoring the Ebola outbreak in Uganda. Though there is nothing new to report medically, the Ugandan Ministry of Health has reported cumulative figures for the Gulu district at 320 cases and 102 deaths, as of this morning.
As always, we hope you enjoy the issue.